About Etcembly
Etcembly is a Healthcare company based in Harwell (United Kingdom) founded in 2020 by Jacob Hurst and Michelle Teng. It operates as a provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy. Etcembly has raised $12.66 million across 4 funding rounds. Its chief executive is Michelle Teng. Etcembly offers products and services including EMLy and Long Term Survivor Study. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Formulation. Its legal entity is ETCEMBLY LTD. Its competitors include Archon Bio, SQALE, Neuromathix, Sprectroo and Protains and 1 more; 1 of its 6 listed competitors has raised funding.
Company details
Etcembly was founded in 2020 and is based in Harwell, United Kingdom. Operations focus on the biotechnology sector, where an AI-based platform is developed to engineer T cell receptors for cancer immunotherapy. Machine learning techniques are employed within the platform to create high-affinity TCRs, enabling treatments with defined speed and precision. Services target advancements in personalized cancer therapies through computational design.
- Headquarters Harwell, United Kingdom
- Founders Jacob Hurst, Michelle Teng
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website etcembly.io
- Social LinkedIn X
- Legal Name Etcembly Ltd
- Date of Incorporation 19 Jun, 2019
- Jurisdiction DIDCOT, OXFORDSHIRE, ENGLAND
- Total Equity Funding$12.66M (USD)
in 4 rounds
- Latest Funding Round$4.53M (USD), Series A
Jun 2023
Products & Services of Etcembly
Etcembly offers a comprehensive portfolio of products and services, including EMLy and Long Term Survivor Study.
AI tool for decoding immune repertoires and designing TCRs.
Program to analyze cancer survivors' immune data for new targets.
Funding Insights of Etcembly
Etcembly has successfully raised a total of $12.66M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.53 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.66M
- Total Rounds 4
- Last Round Series A — $4.53M
- First Round $92,012
(Jan 2020)
All 4 funding rounds of Etcembly with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $4.53M | Series A | – | – | – |
| May 2022 | $5.77M | Series A | – | – | – |
| Nov 2020 | $2.28M | Seed | – | – | – |
| Jan 2020 | $92,012 | Seed | – | – | – |
People of Etcembly
2 people are tracked at Etcembly (2 in leadership).
| Name | Role | Group |
|---|---|---|
Jacob Hurst | Co-Founder & CTO | Leadership |
Michelle Teng | Co-Founder & CEO | Leadership |
Complete people profiles for Etcembly
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Etcembly
3 dated milestones of Etcembly across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Etcembly is founded.
- Funding First funding round of $92K.
- Funding Latest funding round, Series A, of $4.5M.
Competitors of Etcembly
Etcembly has 6 listed competitors in our database, 1 of them funded. They include Archon Bio, SQALE, Neuromathix, Sprectroo and Protains, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archon.bio | 2023 | Seattle, United States | $20M | – | Provider of computational platform to develop protein therapeutics | |
| sqale.ai | 2023 | Copenhagen, Denmark | – | – | Provides bioprocess optimization services for microalgae and precision fermentation companies. | |
| neuromathix.com | 2001 | Brisbane, Australia | – | – | Offers decision support software for personalized healthcare models based on patient data. | |
| sprectroo.com | 2022 | Santa Clara, United States | – | – | Sprectroo is an AI-driven platform for drug derivatization and repurposing. | |
| protains.com | 2024 | – | – | – | AI-driven platform for drug discovery using algorithms and computing resources. | |
| csrnd.com | 1995 | Zurich, Switzerland | – | – | AI-driven tools for accelerating drug discovery processes. |
Detailed competitors of Etcembly
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Etcembly (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Etcembly
Complete news archive for Etcembly
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Etcembly
Etcembly was founded in 2020.
Etcembly is headquartered in Harwell, United Kingdom. It is registered at Harwell, Oxfordshire, United Kingdom.
Michelle Teng is the current CEO of Etcembly. They have also founded this company.
Etcembly is a funded company, having raised a total of $12.66M across 4 funding rounds to date. The company's 1st funding round was a Seed of $92.01K, raised on Jan 2020.
Etcembly was founded in 2020 and is based in Harwell, United Kingdom. Operations focus on the biotechnology sector, where an AI-based platform is developed to engineer T cell receptors for cancer immunotherapy. Machine learning techniques are employed within the platform to create high-affinity TCRs, enabling treatments with defined speed and precision. Services target advancements in personalized cancer therapies through computational design.
Etcembly's top competitors include Archon Bio, SQALE and Neuromathix.
Etcembly offers EMLy and Long Term Survivor Study.
Etcembly operates through Etcembly Ltd.